- Home
- CCBG vs OMER Comparison
CCBG vs OMER Comparison
Compare CCBG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- OMER
- Stock Information
- Founded
- CCBG 1895
- OMER 1994
- Country
- CCBG United States
- OMER United States
- Employees
- CCBG N/A
- OMER N/A
- Industry
- CCBG Major Banks
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CCBG Finance
- OMER Health Care
- Exchange
- CCBG Nasdaq
- OMER Nasdaq
- Market Cap
- CCBG 620.5M
- OMER 530.2M
- IPO Year
- CCBG N/A
- OMER 2009
- Fundamental
- Price
- CCBG $36.38
- OMER $8.37
- Analyst Decision
- CCBG Buy
- OMER Buy
- Analyst Count
- CCBG 3
- OMER 4
- Target Price
- CCBG $38.50
- OMER $22.50
- AVG Volume (30 Days)
- CCBG 25.5K
- OMER 675.4K
- Earning Date
- CCBG 02-04-2025
- OMER 11-13-2024
- Dividend Yield
- CCBG 2.42%
- OMER N/A
- EPS Growth
- CCBG 3.04
- OMER N/A
- EPS
- CCBG 3.04
- OMER N/A
- Revenue
- CCBG $226,023,000.00
- OMER N/A
- Revenue This Year
- CCBG N/A
- OMER N/A
- Revenue Next Year
- CCBG $3.63
- OMER N/A
- P/E Ratio
- CCBG $11.97
- OMER N/A
- Revenue Growth
- CCBG 4.47
- OMER N/A
- 52 Week Low
- CCBG $25.45
- OMER $2.61
- 52 Week High
- CCBG $40.86
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- CCBG 50.59
- OMER 42.71
- Support Level
- CCBG $35.52
- OMER $8.87
- Resistance Level
- CCBG $36.85
- OMER $9.50
- Average True Range (ATR)
- CCBG 0.94
- OMER 0.77
- MACD
- CCBG 0.21
- OMER -0.17
- Stochastic Oscillator
- CCBG 87.79
- OMER 5.25
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.